Search Results - "Dharmadhikari, Abhijeet"

A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults by Kulkarni, Prasad S., Gunale, Bhagwat, Kohli, Sunil, Lalwani, Sanjay, Tripathy, Srikanth, Kar, Sonali, Raut, Sidram, Kulkarni, Praveen, Apte, Aditi, Bavdekar, Ashish, Bhalla, Hira Lal, Plested, Joyce S., Cloney-Clark, Shane, Zhu, MingZhu, Kalkeri, Raj, Pryor, Melinda, Hamilton, Stephanie, Thakar, Madhuri, Sannidhi, Ranga S., Baranwal, Punjita, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Gupta, Manish, Poonawalla, Cyrus S., Shaligram, Umesh, Kapse, Dhananjay

“…Due to waning immunity following primary immunization with COVID-19 vaccines, booster doses may be required. The present study assessed a heterologous booster…”
Get full text

A case control study to assess effectiveness of measles containing vaccines in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children by Gujar, Nilesh, Tambe, Muralidhar, Parande, Malangori, Salunke, Nandkumar, Jagdale, Ganesh, Anderson, Sarah G., Dharmadhikari, Abhijeet, Lakhkar, Anand, Kulkarni, Prasad S.

“…Currently, most licensed vaccines against SARS-CoV-2 infection are approved for adults and not for children. We conducted a test negative case-control study to…”
Get full text

Post-marketing safety surveillance of the rotavirus vaccine in India by Kang, Gagandeep, Lakhkar, Anand, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Narwadkar, Jyoti, Kanujia, Arti, Desai, Sajjad, Gunale, Bhagwat, Poonawalla, Cyrus S., Kulkarni, Prasad S.

“…•Active post-marketing safety surveillance on ROTASIIL, an oral rotavirus vaccine, was conducted in 9940 infants in India.•Three doses of ROTASIIL were…”
Get full text

Single Phase Load Balancing in a Three Phase System at Feeder and Consumer Level by Dharmadhikari, Abhijeet M., Jadhav, H.T.

“…This paper presents load balancing technique of 3 phase system at consumer load and rearrangement of the installation at unit level itself. It will help load…”
Get full text

A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants by Kulkarni, Prasad S., Desai, Sajjad, Tewari, Tushar, Kawade, Anand, Goyal, Nidhi, Garg, Bishan Swarup, Kumar, Dinesh, Kanungo, Suman, Kamat, Veena, Kang, Gagandeep, Bavdekar, Ashish, Babji, Sudhir, Juvekar, Sanjay, Manna, Byomkesh, Dutta, Shanta, Angurana, Rama, Dewan, Deepika, Dharmadhikari, Abhijeet, Zade, Jagdish K., Dhere, Rajeev M., Fix, Alan, Power, Maureen, Uprety, Vidyasagar, Parulekar, Varsha, Cho, Iksung, Chandola, Temsunaro R., Kedia, Vikash K., Raut, Abhishek, Flores, Jorge, Shaikh, Hanif, Gupta, Lalit, Patil, Rakesh, Aslam, Mohd, Arya, Alok, Rafiqi, Farhana, Gupta, Subodh S., Maliye, Chetna H., Bahulekar, P.V., Bala, Kiran, Nazir Shora, Tajali, Hussain, Shahid, Kumar Bhattacharya, Mihir, Mukhopadhyay, Ashis K., Kumar Pal, Dilip, Saha, Jayanta, Shetty, Ranjitha S., Kulkarni, Muralidhar M., Raj, Chythra V.

“…•Pentavalent reassortant rotavirus vaccine was tested for efficacy in infants.•The vaccine (BRV-PV) showed excellent tolerability and a good safety…”
Get full text

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study by Kulkarni, Prasad S, Kawade, Anand, Kohli, Sunil, Munshi, Renuka, Maliye, Chetna, Gogtay, Nithya J, S, Ravish H, Singh, Kiranjit, Vengadakrishnan, K, Panigrahi, Sandeep Kumar, Sahoo, Jyotiranjan, Bavdekar, Ashish, Garg, B S, Raut, Abhishek, Raj, Jeffrey P, Saxena, Unnati, Chaudhari, Vijaya L, Patil, Rakesh, Venkatarao, Epari, Kumari, Nitu, Surendran, Jithin, Parulekar, Varsha, Gagnon, Luc, Gensale, Tania, Dharmadhikari, Abhijeet, Gairola, Sunil, Kale, Sameer, Pisal, Sambhaji S, Dhere, Rajeev M, Mallya, Asha, Poonawalla, Cyrus S, Kapse, Dhananjay

“…Meningococcal disease remains an important public health problem globally. We assessed the non-inferiority and the lot-to-lot consistency of a pentavalent…”
Get full text

The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial by Kulkarni, Prasad S, Potey, Anirudha Vyankatesh, Bharati, Sandesh, Kunhihitlu, Anil, Narasimha, Bharath, Yallapa, Sindhu, Dharmadhikari, Abhijeet, Gavade, Vinay, Kamat, Chandrashekhar D, Mallya, Asha, Sarma, Annamraju D, Goel, Sunil, Pisal, Sambhaji S, Poonawalla, Cyrus S, Venkatesan, Rajaram, Jones, Elizabeth, Flaxman, Amy, Kim, Young Chan, Pollard, Andrew J, McLean, Florence, Pantazi, Eirini, Dinesh, Tanya, Atherton, Rachel, Day, Nicole, Park, Juyeon, Sahoo, Sarthak

“…Enteric fever caused by Salmonella enterica Typhi and Salmonella Paratyphi A is an important public health problem, especially in low-income and middle-income…”
Get full text

Safety and tolerability of a liquid bovine rotavirus pentavalent vaccine (LBRV-PV) in adults by Anil, K., Desai, Sajjad, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Madhusudhan, R.L., Patel, Jaya, Kulkarni, Prasad S.

“…Rotavirus Gastroenteritis (RVGE) is an important global public health problem. Recently a Lyophilized Pentavalent Human Bovine Reassortant Rotavirus vaccine…”
Get full text

Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure by Kang, Gagandeep, Lakhkar, Anand, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Narwadkar, Jyoti, Kanujia, Arti, Kapse, Dhananjay, Gunale, Bhagwat, Poonawalla, Cyrus S., Kulkarni, Prasad S.

“…A vero cell-based inactivated Rabies Vaccine (Rabivax-S) and Rabies Human Monoclonal Antibody (Rabishield) have been approved since 2016. A post-marketing…”
Get full text

Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants by Kawade, Anand, Babji, Sudhir, Kamath, Veena, Raut, Abhishek, Kumar, Chandra Mohan, Kundu, Ritabrata, Venkatramanan, Padmasani, Lalwani, Sanjay K., Bavdekar, Ashish, Juvekar, Sanjay, Dayma, Girish, Patil, Rakesh, Kulkarni, Muralidhar, Hegde, Asha, Nayak, Dinesh, Garg, B.S., Gupta, Subodh, Jategaonkar, Smita, Bedi, Nidhi, Maliye, Chetna, Ganguly, Nupur, Uttam, Kheya Ghosh, Niyogi, Prabal, Palkar, Sonali, Hanumante, Neeta, Goyal, Nidhi, Arya, Alok, Aslam, Mohd, Parulekar, Varsha, Dharmadhikari, Abhijeet, Gaikwad, Dutta, Zade, Jagdish, Desai, Sajjad, Kang, Gagandeep, Kulkarni, Prasad S.

“…A lyophilized bovine-human rotavirus reassortant pentavalent vaccine (BRV-PV, Rotasiil®) was licensed in 2016. A liquid formulation of this vaccine (LBRV-PV,…”
Get full text

Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposureResearch in context by Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Dhananjay Kapse, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni

“…Background: A vero cell-based inactivated Rabies Vaccine (Rabivax-S) and Rabies Human Monoclonal Antibody (Rabishield) have been approved since 2016. A…”
Get full text

A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants by Rathi, Niraj, Desai, Sajjad, Kawade, Anand, Venkatramanan, Padmasani, Kundu, Ritabrata, Lalwani, Sanjay K., Dubey, A.P., Venkateswara Rao, J., Narayanappa, D., Ghildiyal, Radha, Gogtay, Nithya, Venugopal, P., Palkar, Sonali, Munshi, Renuka, Kang, Gagandeep, Babji, Sudhir, Bavdekar, Ashish, Juvekar, Sanjay, Ganguly, Nupur, Niyogi, Prabal, Ghosh Uttam, Kheya, Rajani, H.S., Kondekar, Alpana, Kumbhar, Dipti, Mohanlal, Smilu, Agarwal, Mukesh C, Shetty, Parvan, Antony, Kalpana, Gunale, Bhagwat, Dharmadhikari, Abhijeet, Tang, Yuxiao, Kulkarni, Prasad S., Flores, Jorge

“…•Pentavalent reassortant rotavirus vaccine (BRV-PV) was tested for lot-to-lot consistency in Indian infants.•The vaccine demonstrated safety profile similar to…”
Get full text

Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine by Desai, Sajjad, Rathi, Niraj, Kawade, Anand, Venkatramanan, Padmasani, Kundu, Ritabrata, Lalwani, Sanjay K., Dubey, A.P., Venkateswara Rao, J., Narayanappa, D., Ghildiyal, Radha, Gogtay, Nithya J, Venugopal, P., Palkar, Sonali, Munshi, Renuka, Bavdekar, Ashish, Juvekar, Sanjay, Ganguly, Nupur, Niyogi, Prabal, Uttam, Kheya Ghosh, Kondekar, Alpana, Kumbhar, Dipti, Mohanlal, Smilu, Agarwal, Mukesh C., Shetty, Parvan, Antony, Kalpana, Gunale, Bhagwat, Dharmadhikari, Abhijeet, Deshpande, Jagdish, Nalavade, Uma, Sharma, Deepa, Bansal, Anurag, Tang, Yuxiao, Flores, Jorge, Kulkarni, Prasad S.

“…A newly developed bovine-human reassortant pentavalent vaccine (BRV-PV, ROTASIIL®) was tested for its potential effect on the immunogenicity of concomitantly…”
Get full text

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults by Kulkarni, Prasad S, Padmapriyadarsini, Chandrasekaran, Vekemans, Johan, Bavdekar, Ashish, Gupta, Madhu, Kulkarni, Praveen, Garg, B S, Gogtay, Nithya J, Tambe, Muralidhar, Lalwani, Sanjay, Singh, Kiranjit, Munshi, Renuka, Meshram, Sushant, Selvavinayagam, T S, Pandey, Krishna, Bhimarasetty, Devi Madhavi, Ramakrishnan, S R, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Budhawant, Chandrashekhar, Bonhomme, Cyrille J, Thakar, Madhuri, Kurle, Swarali N, Kelly, Elizabeth J, Gautam, Manish, Gupta, Nivedita, Panda, Samiran, Bhargava, Balram, Poonawalla, Cyrus S, Shaligram, Umesh, Kapse, Dhananjay, Gunale, Bhagwat

“…AZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19…”
Get full text

A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India by Kulkarni, Prasad S, Padmapriyadarsini, Chandrasekaran, Vekemans, Johan, Bavdekar, Ashish, Gupta, Madhu, Kulkarni, Praveen, Garg, B S, Gogtay, Nithya J, Tambe, Muralidhar, Lalwani, Sanjay, Singh, Kiranjit, Munshi, Renuka, Meshram, Sushant, Selvavinayagam, T S, Pandey, Krishna, Bhimarasetty, Devi Madhavi, Ramakrishnan, S R, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Vadakkedath, Rajeev, Bonhomme, Cyrille J, Thakar, Madhuri, Kurle, Swarali N, Kelly, Elizabeth J, Gautam, Manish, Gupta, Nivedita, Panda, Samiran, Bhargava, Balram, Shaligram, Umesh, Kapse, Dhananjay, Gunale, Bhagwat

“…This phase 2/3 immunobridging study evaluated the safety and immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19),…”
Get full text

Response to: Letter from P. Gillard and B. Benninghoff by Rathi, Niraj, Desai, Sajjad, Kawade, Anand, Venkatramanan, Padmasani, Kundu, Ritabrata, Lalwani, Sanjay K., Dubey, A.P., Venkateswara Rao, J., Narayanappa, D., Ghildiyal, Radha, Gogtay, Nithya J., Venugopal, P., Palkar, Sonali, Munshi, Renuka, Kang, Gagandeep, Babji, Sudhir, Bavdekar, Ashish, Juvekar, Sanjay, Ganguly, Nupur, Niyogi, Prabal, Uttam, Kheya Ghosh, Rajani, H.S., Kondekar, Alpana, Kumbhar, Dipti, Mohanlal, Smilu, Agarwal, Mukesh C., Shetty, Parvan, Antony, Kalpana, Gunale, Bhagwat, Dharmadhikari, Abhijeet, Tang, Yuxiao, Kulkarni, Prasad S., Flores, Jorge

Get full text

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study by Kulkarni, Prasad S., Kadam, Abhijit, Godbole, Sheela, Bhatt, Varsha, Raut, Abhishek, Kohli, Sunil, Tripathi, Santanu, Kulkarni, Praveen, Ludam, Rakhi, Prabhu, Madhav, Bavdekar, Ashish, Gogtay, Nithya J., Meshram, Sushant, Kadhiravan, Tamilarasu, Kar, Sonali, Narayana, D.H. Ashwath, Samuel, Clarence, Kulkarni, Govind, Gaidhane, Abhay, Sathyapalan, Dipu, Raut, Sidram, Hadda, Vijay, Bhalla, Hira Lal, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Plested, Joyce S., Cloney-Clarke, Shane, Zhu, Mingzhu, Pryor, Melinda, Hamilton, Stephanie, Thakar, Madhuri, Shete, Ashwini, Gautam, Manish, Gupta, Nivedita, Panda, Samiran, Shaligram, Umesh, Poonawalla, Cyrus S., Bhargava, Balram, Gunale, Bhagwat, Kapse, Dhananjay, Kanitkar, Shubhangi A., Kakrani, Arjun L., Tripathy, Srikanth P., Tilak, Abhijit V., Dhamne, Akshay A., Mirza, Shahzad Beg, Athavale, Prachi V., Bhowmik, Mandakini, Ratnakar, Parag J., Gupta, Subodh, Deotale, Vijayshri, Jain, Jyoti, Kalantri, Ashwini, Jain, Vineet, Goyal, Nidhi, Arya, Alok, Rongsen-Chandola, Temsunaro, Dasgupta, Shreyasi, Periera, Pratibha, A, Vanmathi, Kawade, Anand, Gondhali, Arunkumar, Kudyar, Palvi, Singh, Abhishek, Yadav, Ravi, Alexander, Alina, Gunasekaran, Venugopalan, Dineshbabu, Sekar, Samantaray, P.C., Ravish, H.S., Kamra, Deepshikha, Gaidhane, Shilpa, Zahiruddin, Quazi Syed, Moni, Merlin, Kumar, Anil, Dravid, Ameet, Mohan, Anant, Suri, Tejas, Patel, Tejas K., Kishore, Surekha, Choche, Rahul, Ghatage, Deepak, Salvi, Sugam

“…NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as…”
Get full text

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context by Prasad S. Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Bhatt, Abhishek Raut, Sunil Kohli, Santanu Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya J. Gogtay, Sushant Meshram, Tamilarasu Kadhiravan, Sonali Kar, D.H. Ashwath Narayana, Clarence Samuel, Govind Kulkarni, Abhay Gaidhane, Dipu Sathyapalan, Sidram Raut, Vijay Hadda, Hira Lal Bhalla, Chetanraj Bhamare, Abhijeet Dharmadhikari, Joyce S. Plested, Shane Cloney-Clarke, Mingzhu Zhu, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ashwini Shete, Manish Gautam, Nivedita Gupta, Samiran Panda, Umesh Shaligram, Cyrus S. Poonawalla, Balram Bhargava, Bhagwat Gunale, Dhananjay Kapse, Shubhangi A. Kanitkar, Arjun L. Kakrani, Srikanth P. Tripathy, Abhijit V. Tilak, Akshay A. Dhamne, Shahzad Beg Mirza, Prachi V. Athavale, Mandakini Bhowmik, Parag J. Ratnakar, Subodh Gupta, Vijayshri Deotale, Jyoti Jain, Ashwini Kalantri, Vineet Jain, Nidhi Goyal, Alok Arya, Temsunaro Rongsen-Chandola, Shreyasi Dasgupta, Pratibha Periera, Vanmathi A, Anand Kawade, Arunkumar Gondhali, Palvi Kudyar, Abhishek Singh, Ravi Yadav, Alina Alexander, Venugopalan Gunasekaran, Sekar Dineshbabu, P.C. Samantaray, H.S. Ravish, Deepshikha Kamra, Shilpa Gaidhane, Quazi Syed Zahiruddin, Merlin Moni, Anil Kumar, Ameet Dravid, Anant Mohan, Tejas Suri, Tejas K. Patel, Surekha Kishore, Rahul Choche, Deepak Ghatage, Sugam Salvi

“…Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer…”
Get full text